Roche announces positive results from the phase III IMpower133 study of Tecentriq®
Roche announced positive results from the Phase III IMpower133 study of Tecentriq® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for initial treatment of people with previously-untreated ES-SCLC. The analysis showed Tecentriq and chemotherapy helped people live significantly longer. September 25, 2018